These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 8618112

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens.
    Speciale A, Caccamo F, Blandino G, Giacchi GT, Aleo G, Nicoletti G.
    Chemotherapy; 1996; 42(1):1-10. PubMed ID: 8751262
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.
    Yamada T, Yokota Y, Ikeda F, Mine Y, Kitada T.
    Chemotherapy; 1992; 38(1):28-35. PubMed ID: 1618001
    [Abstract] [Full Text] [Related]

  • 6. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
    Dan M, Poch F, Edelman A, Asherov J, Hafely H, Atzmon Y.
    J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P, Rand KH, Obermann B, Derendorf H.
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Susceptibility of respiratory tract pathogens in Finland to cefixime and nine other antimicrobial agents.
    Lehtonen L, Huovinen P.
    Scand J Infect Dis; 1993 Feb; 25(3):373-8. PubMed ID: 8362234
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G, Aleo G, Caccamo F, Nicolosi VM, Siracusa V, Speciale A.
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [Abstract] [Full Text] [Related]

  • 11. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Bryson HM, Brogden RN.
    Drugs; 1993 Apr; 45(4):589-621. PubMed ID: 7684677
    [Abstract] [Full Text] [Related]

  • 12. [Antibacterial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections (II)].
    Deguchi K, Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Oda S, Tanaka S, Nakane Y, Fukumoto T.
    Jpn J Antibiot; 1994 Dec; 47(12):1753-61. PubMed ID: 7877255
    [Abstract] [Full Text] [Related]

  • 13. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A, Jungwirth R.
    Infection; 1991 Dec; 19(5):353-62. PubMed ID: 1800377
    [Abstract] [Full Text] [Related]

  • 14. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR, Huang WK, Shyr JM, Lau YJ, Liu YC, Luh KT.
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
    Owens RC, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP.
    Int J Antimicrob Agents; 2001 Jun; 17(6):483-9. PubMed ID: 11397619
    [Abstract] [Full Text] [Related]

  • 16. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.
    Bauernfeind A.
    Diagn Microbiol Infect Dis; 1991 Jun; 14(1):89-92. PubMed ID: 2013215
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [Abstract] [Full Text] [Related]

  • 18. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN, Barry AL.
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [Abstract] [Full Text] [Related]

  • 20. Postantibiotic effect of ceftibuten on respiratory pathogens.
    Chin NX, Huang HB, Neu HC.
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S84-7. PubMed ID: 7567315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.